Maryam Lustberg, Director of Breast Center/Chief Breast Oncology at Yale University School of Medicine, shared a post on LinkedIn:
“Current toxicity reporting misses what is below the waterline which is what determines tolerability of cancer therapy․
‘Low’ grade toxicities does not mean low impact.
Tolerable is relative and can only be determined by the individual.
Toxicities also impact families.
Patient advocates are essential to bring context that data alone do not capture.
Amazing talk by Jill Feldman.”
“Clinicians cannot define what is tolerable.
Suggestions for meaningful partnership with patient advocates.
Start day 1.”
Other articles featuring Maryam Lustberg on OncoDaily.
